Foghorn Therapeutics

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities Just now (03:00 PM IST)

Foghorn Cuts 40% of Staff After Lilly Ends Cancer Pact on Data Concerns

Foghorn Therapeutics is laying off about 40% of its workforce after Eli Lilly terminated a cancer drug collaboration that had been a key strategic and financial pillar for the biotech company. The collapse of the partnership, reportedly tied to concerns over data quality, has intensified pressure on Foghorn’s pipeline and sent its shares sharply lower as investors reassess the company’s near-term prospects.

By RDU Global Wire5 min read

Global Markets & EquitiesJust now (02:02 PM IST)

Beam Therapeutics Sues Chinese Biotech and VC-Backed Startup Over Alleged IP Theft

Beam Therapeutics has filed suit against a Chinese biotech company and a venture-capital-backed startup, alleging theft of intellectual property tied to its gene-editing technology, according to STAT. The case adds to mounting tensions over biotech innovation, cross-border technology transfer, and the protection of proprietary research in a sector where patents and trade secrets are central to valuation.

6 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Foghorn Therapeutics:

Washington, D.C.(1)Eli Lilly(1)